Clinical Trials
3 trialsNCT06558773 2026-02-11
GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.
Chinese PLA General Hospital
Phase 2 Recruiting
NCT07138547 2026-01-02
GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT07090538 2025-07-29
GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.
Chinese PLA General Hospital
Phase EARLY_PHASE1 Not yet recruiting